



**PROTECH**

**Factsheet**



**Austria**

**Men who  
have sex  
with men**

# **Inject PrEP to protect?**

The first Pan European study exploring the willingness to use long-acting injectable PrEP to prevent HIV.



**Maastricht University**

# What is the PROTECT Survey?

This online survey was conducted across Europe (Oct 2023 to March 2024) and sought to uncover who may benefit from the innovation that is long-acting injectable PrEP.

The European Commission (EC) has authorized Apretude ® (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention.

It is important for health services and policy makers to understand who may be interested in taking long-acting injectable PrEP so that resources can be most effectively allocated.


**This factsheet reports on data from the PROTECT Survey collected in Austria from men who have sex with men N= 237.**

Austria


237



### SEXUAL ORIENTATION



### AGE




Austria


237



### MIGRANT STATUS



### RELATIONSHIP STATUS




Austria


237



### CHEMSEX (in the past 6 months)



### NUMBER OF SEXUAL PARTNERS (in the past 6 months)






Example of campaign image




HIV TESTING FREQUENCY



- More than every 6 months: 123
- Every 6 months: 39
- Less than once a year: 24
- Once a year: 41
- Never: 10


ORAL PrEP USE HISTORY & CURRENT PrEP REGIMEN

Naive: 92 Current: 123 Former: 22






**AWARENESS OF ORAL PrEP**



**CURRENT PREP USERS – ACCESS TO ORAL PREP**



# Barriers to oral PrEP use

- **31% of the MSM said:**
  - Oral PrEP was too costly (either the pills or the tests associated with PrEP use)
- **13% of the MSM said:**
  - The procedure took too long to obtain oral PrEP when they needed it
- **30% of the MSM said:**
  - Their healthcare provider did not offer oral PrEP to them
- **10% of the MSM said:**
  - There was a waiting list at their healthcare provider for oral PrEP and the service was not available






# Long-acting PrEP: interest and intention

**77%**

are interested in using LA-PrEP if it becomes available.

**58%**

intend to use LA-PrEP if it becomes available.



# What LA-PrEP could mean to participants

This word cloud was generated from responses that participants provided to a question asking them what LA-PrEP could mean to them, if it were to become available.



# Summary & Contact Information

## SUMMARY

- Austrian MSM are aware of PrEP and have taken up oral PrEP
- Barriers to starting PrEP still exist
- Interest and intention to use LA-PrEP among MSM in Austria is high
- LA-PrEP may provide an opportunity for greater HIV prevention in Austria

## CONTACT INFORMATION

- Prof. Dr. Kai J. Jonas  
Email: [kai.jonas@maastrichtuniversity.nl](mailto:kai.jonas@maastrichtuniversity.nl)
- Dr. Johann Kolstee  
Email:  
[johann.kolstee@maastrichtuniversity.nl](mailto:johann.kolstee@maastrichtuniversity.nl)
- Maastricht University postal address  
P.O. Box 616, 6200 MD Maastricht, The Netherlands